Wilson, G., Rodriguez, B., Elizaga, M., Li, S., Allen, M., Frank, I., … Frahm, N. (2018). Safety and Immunogenicity of a pDNA Clade B Env Prime, rVSV Clade C Env Boost HIV-1 Vaccination Regimen in a Phase 1 Clinical Trial. In AIDS RESEARCH AND HUMAN RETROVIRUSES (Vol. 34, pp. 16–16). Madrid, SPAIN: MARY ANN LIEBERT, INC.

Wilson, Gregory, Benigno Rodriguez, Marnie Elizaga, Sue Li, Mary Allen, Ian Frank, Erika Thommes, et al. “Safety and Immunogenicity of a pDNA Clade B Env Prime, rVSV Clade C Env Boost HIV-1 Vaccination Regimen in a Phase 1 Clinical Trial.” In AIDS RESEARCH AND HUMAN RETROVIRUSES, 34:16–16. MARY ANN LIEBERT, INC, 2018.

Wilson G, Rodriguez B, Elizaga M, Li S, Allen M, Frank I, et al. Safety and Immunogenicity of a pDNA Clade B Env Prime, rVSV Clade C Env Boost HIV-1 Vaccination Regimen in a Phase 1 Clinical Trial. In: AIDS RESEARCH AND HUMAN RETROVIRUSES. MARY ANN LIEBERT, INC; 2018. p. 16–16.

Wilson, Gregory, et al. “Safety and Immunogenicity of a pDNA Clade B Env Prime, rVSV Clade C Env Boost HIV-1 Vaccination Regimen in a Phase 1 Clinical Trial.” AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 34, MARY ANN LIEBERT, INC, 2018, pp. 16–16.

Wilson G, Rodriguez B, Elizaga M, Li S, Allen M, Frank I, Thommes E, Trahey M, Kalams S, Pensiero M, Butler C, Hannaman D, Clarke D, Xu R, Egan M, Eldridge J, Montefiori D, Tomaras G, Frahm N. Safety and Immunogenicity of a pDNA Clade B Env Prime, rVSV Clade C Env Boost HIV-1 Vaccination Regimen in a Phase 1 Clinical Trial. AIDS RESEARCH AND HUMAN RETROVIRUSES. MARY ANN LIEBERT, INC; 2018. p. 16–16.